Stefano Baila | Director Of Operation And Business Development
Anemocyte

Stefano Baila, Director Of Operation And Business Development, Anemocyte

Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia.  Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal products through business development and strategic marketing roles at Areta International, a CDMO, and by leading field implementation and commercialization activities for the cell processing unit of Terumo BCT.  Stefano also worked  as Industrialization Manager at Celyad where he led process development and automation efforts for CAR-T therapeutics. Now he serves as Director of Operation and Business Development for Anemocyte.

Appearances:



Conference Day 1 - Tuesday 31st March 2020 @ 14:40

Exploring Manufacturing platforms and Ancillary Materials to address Cell and Gene Therapy Product needs

  • Exploring Manufacturing platforms and Ancillary Materials to address Cell and Gene Therapy PAiming for commercialization of cell and gene therapy products require a robust process development addressing “manufacturability” and “sustainability”, balancing: critical quality attributes, CoGs, needle-to-needle logistics and scale
  • As a Biotech Manufacturing Organization (BMO) we proactively look on how to address the industry bottlenecks. Here among the different parameters we present the impact of culture media (PRIME-XV T Cell CDM) and manufacturing platforms.
last published: 04/Jun/20 08:25 GMT

back to speakers